^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GDF15 inhibitor

    Related drugs:
    9d
    The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies. (PubMed, Med Oncol)
    A good number of preclinical and early clinical studies have shown evidence for both approaches, particularly for Ponsegromab, a Growth Differentiation Factor-15 (GDF-15) inhibitor. Due to the multifactorial nature of cachexia, a multimodal, integrated intervention is a good substitute for the maximum tolerated dose, which can be effective against it. Future directions in cancer therapy should emphasize the development of robust clinical trial designs with cachexia-specific endpoints to advance precision prevention strategies.
    Review • Journal
    |
    GDF15 (Growth differentiation factor 15)
    |
    ponsegromab (PF-06946860)
    24d
    Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=131, Recruiting, CatalYm GmbH
    New P2 trial
    |
    Opdivo (nivolumab) • docetaxel • visugromab (CTL-002)
    29d
    To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants (clinicaltrials.gov)
    P1, N=36, Recruiting, Shenzhen Kexing Pharmaceutical Co., Ltd.
    New P1 trial
    2ms
    GDFATHERHCC01: Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, CatalYm GmbH
    New P2 trial
    |
    Opdivo (nivolumab) • visugromab (CTL-002)
    2ms
    A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue (clinicaltrials.gov)
    P2/3, N=982, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ponsegromab (PF-06946860)
    2ms
    Design of Bicyclic Peptide Tandems Mimicking the Homodimeric GDF15 Protein to Inhibit GDF15-GFRaL-RET Complex Cell Signaling. (PubMed, J Med Chem)
    These dimerized protein mimetics inhibited cell signaling in a functional assay and showed improved pharmacokinetic properties compared with their monomeric counterparts. This is the first example of a homodimeric Bicycle molecule inhibiting receptor complex formation, thereby antagonizing the intracellular signaling response.
    Journal
    |
    GDF15 (Growth differentiation factor 15)
    3ms
    Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference. (PubMed, J Bone Metab)
    The conference also highlighted promising clinical advancements, including the HIPGEN trial on placental-expanded stromal cells for muscle regeneration in hip fracture patients and the ponsegromab study targeting growth/differentiation factor-15 inhibition to mitigate cancer cachexia-associated muscle wasting. This review highlights the integration of basic science, innovative diagnostics, and clinical applications as a promising framework for addressing the complex challenges posed by muscle-wasting disorders. As the field progresses, these insights offer hope for improving the quality of life and survival of affected patients.
    Journal
    |
    GDF15 (Growth differentiation factor 15)
    |
    ponsegromab (PF-06946860)
    3ms
    GDFATHER-NSCLC-01: Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=107, Recruiting, CatalYm GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • visugromab (CTL-002)
    4ms
    The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy. (PubMed, Biomedicines)
    Targeting the GDF15-GFRAL axis appears therapeutically promising: the monoclonal antibody ponsegromab improved cachexia-related outcomes in the PROACC-1 trial, while visugromab combined with nivolumab enhanced immune response in ICI-refractory tumors. Further investigation is warranted to delineate the role of GDF15 across malignancies, refine patient selection, and evaluate combinatorial approaches with existing treatments.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    GDF15 (Growth differentiation factor 15)
    |
    Opdivo (nivolumab) • visugromab (CTL-002) • ponsegromab (PF-06946860)
    4ms
    VINCIT: Visugromab in Cachexia International Trial (clinicaltrials.gov)
    P2/3, N=518, Not yet recruiting, CatalYm GmbH
    New P2/3 trial
    |
    visugromab (CTL-002)
    5ms
    Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC (clinicaltrials.gov)
    P2, N=107, Not yet recruiting, CatalYm GmbH
    New P2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • visugromab (CTL-002)
    6ms
    An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. (clinicaltrials.gov)
    P2, N=136, Recruiting, NGM Biopharmaceuticals, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NGM120